Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Type $ Amount Activity Investigatorsort descending Unit Sponsor Date
A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with… Contract $500.00 Clinical Trial Aaron Scott Cancer Center Division Merck Sharp & Dohme Corp. 02/2021
Prospective Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Colorectal Cancer Contract $99,034.20 Clinical Trial Aaron Scott Cancer Center Division Faeth Therapeutics, Inc. 05/2022
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer Contract $127,173.74 Clinical Trial Aaron Scott Cancer Center Division Academic Gastrointestinal Cancer Consortium 03/2020
A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers Contract $226,383.60 Clinical Trial Aaron Scott Cancer Center Division Apexigen 04/2021
A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naive, HER2-Positive G Contract $194,029.06 Clinical Trial Aaron Scott Cancer Center Division MacroGenics Inc 07/2021
A Phase 1a/B Study to Evaluate the Safety and Tolerability of Etc-1922159 in Advanced Solid Tumours Contract $364,303.75 Clinical Trial Aaron Scott Cancer Center Division PPD Investigator Services, LLC. 01/2022
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcino Contract $337,055.00 Clinical Trial Aaron Scott Cancer Center Division Incyte Corporation 04/2021
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator Phase 2/3 study of Tucatinib in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Subjects with Previously Treated, Locally Contract $453,804.20 Clinical Trial Aaron Scott Cancer Center Division Seagen Inc. 01/2021
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 Agonist Contract $70,892.00 Clinical Trial Aaron Scott Cancer Center Division University of Texas Southwestern Medical Center 02/2022
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. Contract $171,440.00 Clinical Trial Aaron Scott Cancer Center Division Incyte Corporation 05/2020
A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer Contract $299,953.80 Clinical Trial Aaron Scott Cancer Center Division G1 Therapeutics 05/2021
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Sub Contract $557,729.00 Clinical Trial Aaron Scott Cancer Center Division Biosplice Therapeutics, Inc. 04/2022
A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab +/- Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metas Contract $404,272.70 Clinical Trial Aaron Scott Cancer Center Division Leap Therapeutics, Inc. 10/2020
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction... Contract $105,851.40 Clinical Trial Aaron Wolfson Sarver Heart Center Cytokinetics, Incorporated 09/2020
A Phase II Trial of PET-Directed Therapy using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin Plus Nivolumab, Foll Contract $40,100.00 Clinical Trial Abhijeet Kumar Cancer Center Division Mayo Foundation for Medical Education and Research (Mayo Clinic) 06/2020
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. Contract $327,830.00 Clinical Trial Abhijeet Kumar Cancer Center Division Covance, Incorporated 01/2020
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) Contract $323,960.68 Clinical Trial Abhijeet Kumar Cancer Center Division Pharmaceutical Research Associates 04/2022
Accuracy of Arthroscopic vs. Open Reduction of Ankle Syndesmosis Injuries Contract $5,000.00 Research Training Aditya Manoharan Orthopaedic Surgery Orthopaedic Research and Education Foundation 04/2020
A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women with Childhood Adversity Grant $2,437,784.00 Research Aleeca Bell College of Nursing National Institute of Nursing Research 09/2020
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-Resistant Prostate Cancer Contract $227,327.00 Clinical Trial Alejandro Recio Boiles Cancer Center Division Syneos Health 04/2021
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies Contract $468,451.00 Clinical Trial Alejandro Recio Boiles Cancer Center Division Atreca, Inc. 10/2020
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Contract $1,354,476.50 Clinical Trial Alejandro Recio Boiles Cancer Center Division Mirati Therapeutics, Inc. 03/2021
Thrombocyte Regulation of Anti-Parasite Immunity Grant $767,500.00 Research Alfred Bothwell Immunobiology National Institute of Allergy and Infectious Disease 02/2022
2020-2021 Danone North America Gut Microbiome, Yogurt and Probiotics Fellowship Grant Grant $25,000.00 Research Alice Solomon Physiology Danone Institute North America 07/2021
Hormonal Response to Infant Caregiving: A Novel Strategy to Break the Opioid Relapse Cycle During The Postpartum Period Grant $2,302,500.00 Research Alicia Allen Family and Community Medicine Eunice Kennedy Shriver National Institute of Child Health and Human Development 09/2020

Pages